Zymeworks stock holds near $28.27 as market cap tops $2.01 billion

Zymeworks Inc. (US98986T1088) trades with a market value of $2.01 billion and a quoted price of $28.27 as of August 29, 2026, with the same snapshot showing a -2.55% daily move and NasdaqGS:ZYME as the listed symbol.

Market snapshot

The visible market data leaves the stock framed by size rather than a fresh company filing, and the key comparison is simple: $2.01 billion of market cap against a $28.27 share price on August 29, 2026.

A separate market scan also points to negative operating context for the broader biotech screen, where ZYME appears in a ranked list with an EBITDA figure of -$133.34 million and a valuation line of 3.94 debt to equity.

Reported figures

The latest company-context figure visible in the search set is a biotechnology profile that also lists a market cap of $2.01 billion, reinforcing the same size estimate on August 29, 2026.

That profile places Zymeworks in the U.S. biotech group, and the visible numeric spread is still the most useful investor cue here: $28.27 per share, -2.55% on the day, and $2.01 billion in market value.

Product focus

zanidatamab remains the clearest representative product for Zymeworks, and it is the program most closely tied to the company's oncology pipeline and partner-facing commercial story.

Closing view

For market watchers, Zymeworks stock is still a size-and-pipeline name first, and the current anchor is the $28.27 quote and $2.01 billion market cap shown on August 29, 2026.

Fact box

Company: Zymeworks Inc.
ISIN: US98986T1088
Ticker: ZYME
Exchange: Nasdaq
Price (as of August 29, 2026): $28.27 USD
Market cap: $2.01 billion (as of August 29, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq biotechnology universe